Bianco, Claudia
Bianco, Claudia
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA
2017 Rossetti, Barbara; Meini, Genny; Bianco, Claudia; Lamonica, Silvia; Mondi, Annalisa; Belmonti, Simone; Fanti, Iuri; Ciccarelli, Nicoletta; Di Giambenedetto, Simona; Zazzi, Maurizio; De Luca, Andrea
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study
2014 Bianco, Claudia; Rossetti, Barbara; Gagliardini, Roberta; Lamonica, S; Fanti, L; Lombardi, Francesca; Cauda, Roberto; Di Giambenedetto, Simona; De Luca, Andrea
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host
2014 Bianco, Claudia; Arena, Fabio; Rossetti, Barbara; Tordini, Giacinta; Migliorini, Lucia; Galluzzi, Paolo; Cerase, Alfonso; De Luca, Andrea; Rossolini, Gian Maria; Montagnani, Francesca
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
2014 Gagliardini, Roberta; Rossetti, Barbara; Bianco, Claudia; Rusconi, S; Colafigli, Manuela; Prinapori, R; Francisci, D; Fantauzzi, A; Orofino, G; Vignale, F; Di Giambenedetto, Simona; De Luca, Andrea
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
2014 Bianco, Claudia; Meini, G; Rossetti, Barbara; Lamonica, S; Mondi, Annalisa; Belmonti, S; Fanti, L; Ciccarelli, Nicoletta; Di Giambenedetto, Simona; Zazzi, M; De Luca, Andrea
Treatment of HCV infection with the novel NS3/4A protease inhibitors
2014 De Luca, Andrea; Bianco, Claudia; Rossetti, Barbara
| Data di pubblicazione | Titolo | Autore(i) | File |
|---|---|---|---|
| 1-gen-2017 | Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA | Rossetti, Barbara; Meini, Genny; Bianco, Claudia; Lamonica, Silvia; Mondi, Annalisa; Belmonti, Simone; Fanti, Iuri; Ciccarelli, Nicoletta; Di Giambenedetto, Simona; Zazzi, Maurizio; De Luca, Andrea | |
| 1-gen-2014 | Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study | Bianco, Claudia; Rossetti, Barbara; Gagliardini, Roberta; Lamonica, S; Fanti, L; Lombardi, Francesca; Cauda, Roberto; Di Giambenedetto, Simona; De Luca, Andrea | |
| 1-gen-2014 | First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host | Bianco, Claudia; Arena, Fabio; Rossetti, Barbara; Tordini, Giacinta; Migliorini, Lucia; Galluzzi, Paolo; Cerase, Alfonso; De Luca, Andrea; Rossolini, Gian Maria; Montagnani, Francesca | |
| 1-gen-2014 | Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study | Gagliardini, Roberta; Rossetti, Barbara; Bianco, Claudia; Rusconi, S; Colafigli, Manuela; Prinapori, R; Francisci, D; Fantauzzi, A; Orofino, G; Vignale, F; Di Giambenedetto, Simona; De Luca, Andrea | |
| 1-gen-2014 | Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA | Bianco, Claudia; Meini, G; Rossetti, Barbara; Lamonica, S; Mondi, Annalisa; Belmonti, S; Fanti, L; Ciccarelli, Nicoletta; Di Giambenedetto, Simona; Zazzi, M; De Luca, Andrea | |
| 1-gen-2014 | Treatment of HCV infection with the novel NS3/4A protease inhibitors | De Luca, Andrea; Bianco, Claudia; Rossetti, Barbara |